Logo
x

Search category

Subscribe Now

All Posts by Date

Janssen Reports Results of Tremfya (guselkumab) in P-III Studies Demonstrated Durable Efficacy Across Joint and Axial Symptoms for Active Psoriatic Arthritis

Janssen Reports Results of Tremfya (guselkumab) in P-III Studies Demonstrated Durable Efficacy Across Joint and Axial Symptoms for...

PharmaShots Interview: In Conversation with Amolyt’s CEO, Thierry Abribat, Where he Shares Insights on Amolyt as a Key Player in Hypoparathyroidism Space

PharmaShots Interview: In Conversation with Amolyt’s CEO, Thierry Abribat, Where he Shares Insights on Amolyt as a Key Player in H...

Astellas Entered into a Research Collaboration and License Agreement with GO Therapeutics to Develop Novel Immuno-Oncology Therapies

Astellas Entered into a Research Collaboration and License Agreement with GO Therapeutics to Develop Novel Immuno-Oncology Therapi...

Timber Pharmaceuticals’ TMB-001 Receives the US FDA’s Breakthrough Therapy Designation for the Treatment of Congenital Ichthyosis

Timber Pharmaceuticals’ TMB-001 Receives the US FDA’s Breakthrough Therapy Designation for the Treatment of Congenital Ichthyosis

Lannett Reports Updates of Biosimilar Insulin Glargine

Lannett Reports Updates of Biosimilar Insulin Glargine

Samsung Bioepis Presents Results of SB5 (biosimilar, adalimumab) in P-I and (PROPER) Study for Rheumatoid Arthritis and Other Inflammatory Diseases at EULAR 202

Samsung Bioepis Presents Results of SB5 (biosimilar, adalimumab) in P-I and (PROPER) Study for Rheumatoid Arthritis and Other Infl...

Image

Stay Connected

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2022 PharmaShots - All Rights Reserved.